 Outlook Therapeutics NASDAQ:OTLK Inc, a pre-commercial biopharmaceutical company working to develop the first US Food and Drug Administration FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, said it has appointed Julia A Haller, MD, to the companys board of directors. As one of the worlds most accomplished professionals in ophthalmic education, research, and clinical ophthalmic practice, she will add tremendous value and insight to Outlook Therapeutics NASDAQ:OTLK, Randy Thurman, executive chair of Outlook Therapeutics said in a statement. 